Unlock your financial potential trading stocks!
March 21, 2019 by Sultan
March 21, 2019 by Sultan
March 21, 2019 by Jason F.
Today Adma Biologics (Nasdaq: ADMA) sold off ~10% closing at $3.50. Most of us already in Adma were not phased. Personally, I saw this as a healthy pullback. Since February 1st ADMA has gained 25% … [Read More...] about ADMA Presents Potential Entry For Investors On The Sideline
GALT has updated their NASH-CX presentation. Click here to view the form 8-K and presentation. On March 06, 2019 GALT filed registration statements of a rights offering of common stock and … [Read More...] about GALT Updates NASH-RX Presentation
Amarin (Nasdaq: AMRN) made perhaps the biggest splash in the small-cap biopharmaceutical space last year by announcing trial results from its long-running REDUCE-IT study. The company has a market cap … [Read More...] about Amarin Corporation – A Whale of a Story
Geron Corporation (Nasdaq: GERN) is a clinical stage pharmaceutical company with a current market cap of just over $300 million. Geron has one drug in its pipeline, a telomerase inhibitor called … [Read More...] about Geron: The Neverending Story
For this move, we are buying the panic. Insys Therapeutics (Nasdaq: INSY) has dropped significantly in the past few weeks. The downtrend started following INSY's fourth-quarter 2018 earnings … [Read More...] about Buying The Panic
According to Elliot wave theory and Fibonacci ratio, GALT is showing bullish signs of reversal. GALT ran up from $3.19 to $6.06. It has since pulled back to ~$4.19 (also, .786 retracement) #KEY … [Read More...] about (Nasdaq: GALT) Galectin Therapeutics, Reversal?
Barring a few hiccups heading into March, the first quarter of 2019 has been among the best three months in recent history. After a January that saw the broad market gain nearly 8 percent, February … [Read More...]
Thinly traded Curis, Inc. (NASDAQ: CRIS) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it … [Read More...]
Recro Pharma Inc (NASDAQ: REPH) shares were crashing Monday in reaction to an adverse regulatory decision on its lead pain medication candidate that was announced late Friday. What Happened Recro, a … [Read More...]
Bethesda, Maryland, March 25, 2019 (GLOBE NEWSWIRE) -- Bethesda, MD, March 20, 2019 - The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), along with Uniformed … [Read More...]
MONTREAL, March 25, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for … [Read More...]
KNOXVILLE, TN, March 25, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB:PVCT) today announced the appointment of Heather Raines as the Company's Chief Financial Officer (CFO). Mrs. Raines had previously … [Read More...]
